EZH2 in Myeloid Malignancies.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
08 07 2020
Historique:
received: 12 06 2020
revised: 01 07 2020
accepted: 02 07 2020
entrez: 12 7 2020
pubmed: 12 7 2020
medline: 13 4 2021
Statut: epublish

Résumé

Our understanding of the significance of epigenetic dysregulation in the pathogenesis of myeloid malignancies has greatly advanced in the past decade. Enhancer of Zeste Homolog 2 (EZH2) is the catalytic core component of the Polycomb Repressive Complex 2 (PRC2), which is responsible for gene silencing through trimethylation of H3K27. EZH2 dysregulation is highly tumorigenic and has been observed in various cancers, with EZH2 acting as an oncogene or a tumor-suppressor depending on cellular context. While loss-of-function mutations of EZH2 frequently affect patients with myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndrome and myelofibrosis, cases of chronic myeloid leukemia (CML) seem to be largely characterized by EZH2 overexpression. A variety of other factors frequently aberrant in myeloid leukemia can affect PRC2 function and disease pathogenesis, including Additional Sex Combs Like 1 (

Identifiants

pubmed: 32650416
pii: cells9071639
doi: 10.3390/cells9071639
pmc: PMC7407223
pii:
doi:

Substances chimiques

ASXL1 protein, human 0
Repressor Proteins 0
EZH2 protein, human EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43
Polycomb Repressive Complex 2 EC 2.1.1.43

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Adv Med Sci. 2019 Sep;64(2):395-401
pubmed: 31331874
Leukemia. 2017 Sep;31(9):1936-1943
pubmed: 28626218
Blood. 2018 Aug 30;132(9):948-961
pubmed: 29967129
Leukemia. 2014 Dec;28(12):2292-9
pubmed: 25212276
BMC Cancer. 2012 Jul 23;12:304
pubmed: 22823977
Blood. 2012 Feb 2;119(5):1208-13
pubmed: 22053108
Blood. 2016 Sep 1;128(9):1246-59
pubmed: 27268087
Cancer Cell. 2018 Feb 12;33(2):274-291.e8
pubmed: 29438697
Leukemia. 2012 Jul;26(7):1701-3
pubmed: 22266912
Nature. 2007 Oct 11;449(7163):731-4
pubmed: 17713478
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
Leuk Res. 2016 Jun;45:24-32
pubmed: 27070757
Exp Hematol. 2018 Aug;64:33-44.e5
pubmed: 29751067
Haematologica. 2014 Dec;99(12):1772-83
pubmed: 25472952
Blood. 2011 Nov 10;118(19):5227-34
pubmed: 21921040
Cancer Discov. 2016 Nov;6(11):1248-1257
pubmed: 27630125
Cancer Cell. 2015 May 11;27(5):617-30
pubmed: 25965569
J Cancer Res Clin Oncol. 2018 Jun;144(6):1065-1077
pubmed: 29594337
Cell Rep. 2016 Oct 25;17(5):1453-1461
pubmed: 27783956
J Clin Invest. 2011 Jan;121(1):396-409
pubmed: 21157039
Cell Rep. 2017 Oct 17;21(3):628-640
pubmed: 29045832
Blood. 2006 Mar 1;107(5):2170-9
pubmed: 16293602
J Exp Med. 2013 Nov 18;210(12):2627-39
pubmed: 24218139
Ann Hematol. 2011 Jun;90(6):643-53
pubmed: 21125401
Leukemia. 2017 Apr;31(4):861-871
pubmed: 27694924
Mol Cell. 2018 May 3;70(3):422-434.e6
pubmed: 29681499
Cancer Cell. 2015 May 11;27(5):631-43
pubmed: 25965570
Nat Genet. 2010 Aug;42(8):665-7
pubmed: 20601954
Blood. 2014 Jan 23;123(4):541-53
pubmed: 24255920
Nat Rev Cancer. 2005 Mar;5(3):172-83
pubmed: 15719031
Nature. 2011 Jan 20;469(7330):343-9
pubmed: 21248841
Blood. 2015 Sep 3;126(10):1172-83
pubmed: 26219303
J Clin Oncol. 2012 Sep 20;30(27):3376-82
pubmed: 22869879
J Clin Oncol. 2011 Jun 20;29(18):2499-506
pubmed: 21576631
Blood. 2012 Aug 2;120(5):1107-17
pubmed: 22677129
Cancers (Basel). 2019 Jun 17;11(6):
pubmed: 31213012
Blood Cancer J. 2011 Aug;1(8):e33
pubmed: 22829192
Int J Hematol. 2017 Jan;105(1):23-30
pubmed: 27830540
Nature. 2012 Aug 16;488(7411):404-8
pubmed: 22842901
Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):20980-5
pubmed: 21078963
J Clin Oncol. 2013 Jul 1;31(19):2428-36
pubmed: 23690417
Nature. 2002 Oct 10;419(6907):624-9
pubmed: 12374981
Nat Biotechnol. 2014 Sep;32(9):941-6
pubmed: 24952903
Nature. 2006 Feb 16;439(7078):871-4
pubmed: 16357870
Blood Rev. 2016 Jul;30(4):285-95
pubmed: 26969414
Leukemia. 2013 Jun;27(6):1301-9
pubmed: 23486531
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Leuk Res. 2017 Dec;63:90-97
pubmed: 29127861
Blood. 2011 Oct 6;118(14):3932-41
pubmed: 21828135
PLoS One. 2013 Apr 17;8(4):e61341
pubmed: 23613835
Nature. 2011 Sep 11;478(7367):64-9
pubmed: 21909114
J Clin Oncol. 2006 Jan 10;24(2):268-73
pubmed: 16330673
Blood. 2012 Apr 5;119(14):3203-10
pubmed: 22323480
Cancer Cell. 2012 Aug 14;22(2):180-93
pubmed: 22897849
Clin Cancer Res. 2011 May 1;17(9):2613-8
pubmed: 21367748
Blood. 1998 Dec 1;92(11):4031-5
pubmed: 9834205
Cancer Discov. 2019 Sep;9(9):1228-1247
pubmed: 31189531
J Exp Med. 2016 Jul 25;213(8):1459-77
pubmed: 27401345
Blood. 2011 Dec 22;118(26):6920-9
pubmed: 22031865
Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5028-33
pubmed: 22396593
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Leukemia. 2018 Jun;32(6):1458-1465
pubmed: 29479066
Nat Immunol. 2016 Sep;17(9):1016-24
pubmed: 27478938
N Engl J Med. 2011 Jun 30;364(26):2496-506
pubmed: 21714648
Leukemia. 2011 Jul;25(7):1200-2
pubmed: 21455215
Blood Cancer J. 2018 Nov 12;8(11):113
pubmed: 30420667
Drugs. 2020 Apr;80(5):513-521
pubmed: 32166598
J Vis Exp. 2018 Apr 10;(134):
pubmed: 29708546
Nat Med. 2014 Dec;20(12):1472-8
pubmed: 25326804
Blood. 2012 May 10;119(19):4480-5
pubmed: 22431577
Leukemia. 2014 Feb;28(2):241-7
pubmed: 24220272
Blood. 2012 Feb 9;119(6):1501-10
pubmed: 22184410
Nat Commun. 2014 Jun 23;5:4177
pubmed: 24953053
Blood. 2010 Aug 5;116(5):731-9
pubmed: 20445021
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699
pubmed: 24030381
Leukemia. 2020 Apr 22;:
pubmed: 32322039
Nat Med. 2016 Feb;22(2):128-34
pubmed: 26845405
J Exp Med. 2016 Jul 25;213(8):1479-96
pubmed: 27401344
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Nat Genet. 2010 Feb;42(2):181-5
pubmed: 20081860
Leukemia. 2005 Feb;19(2):245-52
pubmed: 15618963
Nat Med. 2017 Jan;23(1):69-78
pubmed: 27941792
Blood. 2017 Jan 5;129(1):38-47
pubmed: 27733357
Nature. 1985 Jun 13-19;315(6020):550-4
pubmed: 2989692
Nat Genet. 2010 Aug;42(8):722-6
pubmed: 20601953
Cancer Discov. 2016 Nov;6(11):1237-1247
pubmed: 27630126

Auteurs

Jenny Rinke (J)

Klinik für Innere Medizin II, Universitätsklinikum Jena, 07743 Jena, Germany.

Andrew Chase (A)

School of Medicine, University of Southampton, Southampton SO17 1BJ, UK.
Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury SP2 8BJ, UK.

Nicholas C P Cross (NCP)

School of Medicine, University of Southampton, Southampton SO17 1BJ, UK.
Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury SP2 8BJ, UK.

Andreas Hochhaus (A)

Klinik für Innere Medizin II, Universitätsklinikum Jena, 07743 Jena, Germany.

Thomas Ernst (T)

Klinik für Innere Medizin II, Universitätsklinikum Jena, 07743 Jena, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH